WO2025201531 - TRICYCLIC COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/201531
Publication Date
02.10.2025
International Application No.
PCT/CN2025/085858
International Filing Date
28.03.2025
Title **
[English]
TRICYCLIC COMPOUND AND USE THEREOF
[French]
COMPOSÉ TRICYCLIQUE ET SON UTILISATION
[Chinese]
三环类化合物及其用途
Applicants **
SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD.
Inventors
CHEN, Jie
LIU, Zhiqiang
WU, Yuhang
XIE, Dewei
CHEN, Bin
WANG, Shaohui
Priority Data
202410383401.3
29.03.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2523 | |
| EPO | Filing, Examination, Granting | 20331 | |
| Japan | Filing, Examination, Granting | 2595 | |
| South Korea | Filing, Examination, Granting | 3039 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
35,028
Contact Us
Abstract[English]
Provided is a compound represented by formula (I). The compound can modulate a KIF18A protein, thereby affecting a cell cycle and a cell proliferation process to treat cancers and cancer-associated diseases. Further provided are a pharmaceutical composition comprising the compound and a method for treating KIF18A activity-associated conditions.[French]
L'invention concerne un composé représenté par la formule (I). Le composé peut moduler une protéine KIF18A, influant ainsi sur un cycle cellulaire et un processus de prolifération cellulaire pour traiter des cancers et des maladies associées au cancer. L'invention concerne en outre une composition pharmaceutique comprenant le composé et une méthode de traitement d'états associés à l'activité de KIF18A.[Chinese]
提供一种式(I)所示的化合物，该化合物具有能够调节KIF18A蛋白，从而影响细胞周期和细胞增殖过程以治疗癌症和癌症相关疾病。还包括包含所述化合物的药物组合物以及用于治疗与KIF18A活性相关的病况的方法。